Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. 

At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma.

Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology.

For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW. 

Woodline Partners

BlackRock

Commodore Capital

Nextech Invest

Surveyor Capital

T. Rowe Price

Vida Ventures

Fidelity

Fidelity Management and Research Company

Google Ventures

Invus

Kronos Bio

This week our team enjoyed a lunch and learn with Martin Larke, Senior Scientist, Computational Biology, about how we are using machine learning to understand cellular response to stress. This is an important topic in oncology research and one that is central to Kronos Bios’ development of therapeutics that target deregulated transcription. Thanks Martin for such an engaging session!

Members of the Kronos Bio team were busy this week at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. We shared our progress developing therapeutics that target deregulated transcription with investors and potential partners, including the latest on our first internally discovered molecule, KB-0742, a CDK9 inhibitor, as well as our new development candidate, KB-9558, a p300 KAT inhibitor. Thanks to everyone who met with us at #JPM. We appreciate your time, interest, and insights. 2024 is off to a good start!

- with Norbert Bischofberger, Barbara Kosacz, Jorge DiMartino, Christopher Dinsmore, Charles Lin, Sarah Connors, and Margaux Bennett

Wishing you and your family health, happiness and success in 2024!

Today, Kronos Bio announced updates to our pipeline including a new development candidate, KB-9558, which targets the KAT domain of p300, for use in multiple myeloma. To learn more, check out our press release here: https://lnkd.in/eNzhCYTK 

Richard Cutler, Ph.D., Vice President of Clinical Science at Kronos Bio, enjoyed presenting a Trial in Progress poster on our CDK9 inhibitor KB-0742 in triple negative breast cancer at the San Antonio Breast Cancer Symposium (SABCS). With more than 10,000 clinicians and scientists from all over the world, SABCS represents a great opportunity for scientific exchange on the latest in breast cancer research. Thank you Rich for representing Kronos Bio!

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory			-24.81M -	-25.21M 1.64%	-5.58M 77.89%	-5.17M 7.32%
average payables		1.14M -	3.03M 165.27%	2.77M 8.39%	3.02M 8.96%	2.96M 1.90%
average receivables		99K -	405K 309.09%	714K 76.30%	694K 2.80%	286K 58.79%
book value per share	-0.26 -	-0.82 218.02%	28.60 3,606.92%	6.30 77.96%	4.35 30.98%	2.75 36.68%
capex per share	-0.04 -	-0.10 174.23%	-0.59 467.32%	-0.08 86.76%	-0.01 86.80%	-0.01 14.53%
capex to depreciation	-11.81 -	-8.28 29.90%	-11.40 37.72%	-2.15 81.11%	-0.25 88.18%	-0.14 45.76%
capex to operating cash flow	0.17 -	0.20 17.12%	0.25 29.11%	0.04 85.69%	0.01 82.43%	0.01 36.16%
capex to revenue						-0.11 -
cash per share	0.36 -	3.24 801.47%	38.53 1,089.11%	8.78 77.21%	4.24 51.73%	3.00 29.31%
days of inventory on hand
days payables outstanding						65.56 -
days sales outstanding
debt to assets	0.06 -	0.01 91.59%	0.06 1,117.95%	0.09 37.71%	0.11 22.23%	0.13 25.75%
debt to equity	-0.11 -	-0.02 78.47%	0.07 402.67%	0.10 42.05%	0.13 29.98%	0.18 39.76%
dividend yield
earnings yield	-0.01 -	-0.02 129.40%	-0.13 558.46%	-0.20 52.02%	-1.42 608.70%	-1.56 9.92%
enterprise value	760.74M -	738.15M 2.97%	56.20M 92.39%	438.35M 679.97%	46.16M 89.47%	36.13M 21.74%
enterprise value over ebitda	-116.07 -	-44.85 61.36%	-0.66 98.52%	-2.90 336.53%	-0.34 88.40%	-0.32 5.89%
ev to operating cash flow	-118.11 -	-48.94 58.56%	-1.48 96.97%	-3.72 150.76%	-0.51 86.34%	-0.46 9.45%
ev to sales						5.75 -
free cash flow per share	-0.26 -	-0.63 139.89%	-2.92 360.31%	-2.23 23.50%	-1.63 27.04%	-1.37 15.69%
free cash flow yield	-0.01 -	-0.02 139.89%	-0.10 317.16%	-0.16 68.15%	-1.01 512.06%	-1.10 9.26%
graham net net	-0.34 -	-1.18 246.51%	34.18 2,997.89%	7.94 76.78%	3.26 58.97%	2.06 36.82%
graham number	1.17 -	3.15 170.10%	50.33 1,496.25%	19.65 60.96%	15.01 23.64%	11.00 26.71%
income quality	0.96 -	0.94 2.35%	0.43 54.19%	0.78 82.09%	0.68 12.55%	0.70 2.17%
intangibles to total assets	0 -	0	0	0	0	0
interest coverage	-87.43 -		-14.92 -		60.51 -	-12.99 121.46%
interest debt per share	0.03 -	0.02 37.66%	2.21 11,802.03%	0.62 72.08%	0.51 16.82%	0.65 26.38%
inventory turnover
invested capital	-0.11 -	-0.02 78.47%	0.07 402.67%	0.10 42.05%	0.13 29.98%	0.18 39.76%
market cap	770.20M -	770.20M 0%	486.20M 36.87%	744.10M 53.04%	91.05M 87.76%	72.18M 20.72%
net current asset value	-9.37M -	-32.59M 247.81%	373.36M 1,245.76%	301.18M 19.33%	193.85M 35.63%	124.58M 35.74%
net debt to ebitda	1.44 -	1.95 34.94%	5.09 161.24%	2.02 60.21%	0.33 83.83%	0.32 3.39%
net income per share	-0.24 -	-0.54 129.40%	-3.94 626.56%	-2.72 30.84%	-2.30 15.52%	-1.95 15.18%
operating cash flow per share	-0.23 -	-0.53 134.16%	-2.33 339.39%	-2.15 7.53%	-1.62 24.88%	-1.36 15.88%
payables turnover						5.57 -
receivables turnover
research and ddevelopement to revenue						13.10 -
return on tangible assets	-0.53 -	-0.15 71.82%	-0.13 16.63%	-0.38 204.26%	-0.44 15.10%	-0.53 20.51%
revenue per share						0.11 -
roe	0.92 -	0.66 27.87%	-0.14 120.72%	-0.43 213.84%	-0.53 22.39%	-0.71 33.94%
roic	1.15 -	0.73 37.10%	-0.08 110.93%	-0.36 356.01%	-0.43 19.84%	-0.56 28.83%
sales general and administrative to revenue						6.64 -
shareholders equity per share	-0.26 -	-0.82 218.02%	28.60 3,606.92%	6.30 77.96%	4.35 30.98%	2.75 36.68%
stock based compensation to revenue						3.97 -
tangible asset value	-7.30M -	-23.20M 218.02%	465.52M 2,106.29%	345.10M 25.87%	244.50M 29.15%	159.08M 34.94%
tangible book value per share	-0.26 -	-0.82 218.02%	28.60 3,606.92%	6.30 77.96%	4.35 30.98%	2.75 36.68%
working capital	9.23M -	90.61M 881.65%	406.95M 349.14%	333.93M 17.94%	222.81M 33.28%	154.08M 30.84%

COM:KRONOSBIO

Kronos Bio, Inc.

Last Close

0.87

22/11 21:00

Market Cap

75.72M

Beta: -

Volume Today

96.67K

Avg: -

Preview